Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 200

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 200
---
, and we may also elect to enter into agreements with additional or alternative parties in the future.

Commercialization, Sales and Marketing

Given our stage of development,
we do not currently have an established internal sales, marketing or distribution infrastructure. If our product candidates are approved
for marketing, we intend to commercialize our product candidates either alone or in partnership with others, where appropriate, to maximize
the value of our product candidates. We expect to build our commercial infrastructure using a focused and efficient approach, initially,
establishing market access, sales and marketing capabilities in a targeted manner that is appropriate for the relevant product opportunity.
We believe that this approach will allow us to effectively reach patients and physicians and to maximize the commercial potential of our
product candidates.

Kadimastem Business

Kadimastem is a clinical-stage pharmaceutical
company focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell products based on its technology
platform for the expansion and differentiation of human embryonic stem cells, or hESCs, into functional cells.

Kadimastem’s vision is to:

  Replace, restore and repair the functionality of diseased                                                          

  Commercialize its proprietary cell lines optimized for both                           

Kadimastem is primarily developing two products:

  AstroRx ®, Kadimastem’s lead product,                                                                                                       

  IsletRx is Kadimastem’s treatment for diabetes. IsletRx                                                                                  
  is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure  
  patients with Type 1 diabetes and possibly Type 2 insulin dependent diabetes.                                                            
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Kadimastem was founded by Professor Michel Revel,
Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel
received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide.
Kadimastem is currently listed on the TASE (TASE: KDST).

Kadimastem Overview

Kadimastem is a clinical stage biotechnology company,
with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical
needs. Kadimastem operates in the field of development of cell therapy, regenerative medicine, for the treatment of, among